Last Price$228.1(1.8%)
Market Cap$16.9B
LTM Long-Term Investments
$202.1M
YoY Growth
-3.8%
3Y CAGR
-0.9%
5Y CAGR
+1.0%
Stock quality & Intrinsic value
6/10
33.0% overvalued
West Pharmaceutical Services, Inc. Long-Term Investments
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Investments | $27.7M | $29.7M | $31.7M | $33.6M | $38.2M | $48.2M | $56.2M | $59.8M | $60.9M | $60.6M | $61.3M | $82.7M | $85.8M | $91.2M | $192.7M | $214.7M | $207.7M | $204.9M | $210.0M | $202.1M |
Overvalued or undervalued?
Check the intrinsic value for WST
and see if it's the right time to invest.
West Pharmaceutical Services, Inc. (WST) Long-Term Investments comparison analysis
General
LTM Long-Term Investments
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
West Pharmaceutical Services, Inc.WST
$202.1M
(3.8%)
(0.9%)
1.0%
Median Peer Set
$4,300.0K
(21.9%)
(12.8%)
0.0%
Intuitive Surgical, Inc.ISRG
$4,819.1M
127.3%
3.0%
12.9%
Alcon Inc.ALC
$751.0M
174.2%
143.5%
66.3%
Baxter International Inc.BAX
$109.0M
(43.8%)
(10.9%)
7.5%
Hologic, Inc.HOLX
$47.9M
N/A
N/A
N/A
Masimo CorporationMASI
$8,600.0K
(92.3%)
(14.6%)
5.8%
Becton, Dickinson and CompanyBDX
$0.0
(100.0%)
(100.0%)
(100.0%)
AptarGroup, Inc.ATR
$0.0
(100.0%)
(100.0%)
(100.0%)
The Cooper Companies, Inc.COO
$0.0
N/A
(100.0%)
N/A
Repligen CorporationRGEN
$0.0
N/A
N/A
N/A
ResMed Inc.RMD
$0.0
(100.0%)
(100.0%)
(100.0%)
WST key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 699.7 29.2% | 913.3 30.5% | 1,020.1 11.7% | 1,051.1 3.0% | 1,055.7 0.4% | 1,104.7 4.6% | 1,192.3 7.9% | 1,266.4 6.2% | 1,368.4 8.1% | 1,421.4 3.9% | 1,399.8 (1.5%) | 1,509.1 7.8% | 1,599.1 6.0% | 1,717.4 7.4% | 1,839.9 7.1% | 2,146.9 16.7% | 2,831.6 31.9% | 2,886.9 2.0% | 2,949.8 2.2% | 2,893.2 (1.9%) |
| Cost of Goods Sold (COGS) | 507.1 | 651.5 | 728.3 | 748.5 | 752.1 | 786.6 | 853.0 | 878.7 | 933.7 | 973.6 | 944.0 | 1,008.0 | 1,086.5 | 1,172.0 | 1,234.2 | 1,379.1 | 1,655.8 | 1,750.7 | 1,820.6 | 1,894.7 |
% margin | 192.6 27.5% | 261.8 28.7% | 291.8 28.6% | 302.6 28.8% | 303.6 28.8% | 318.1 28.8% | 339.3 28.5% | 387.7 30.6% | 434.7 31.8% | 447.8 31.5% | 455.8 32.6% | 501.1 33.2% | 512.6 32.1% | 545.4 31.8% | 605.7 32.9% | 767.8 35.8% | 1,175.8 41.5% | 1,136.2 39.4% | 1,129.2 38.3% | 998.5 34.5% |
| Operating Expenses | 121.7 | 160.8 | 168.6 | 191.9 | 197.6 | 213.3 | 221.7 | 251.3 | 272.8 | 266.0 | 267.1 | 276.6 | 281.7 | 303.2 | 311.6 | 360.9 | 423.5 | 402.2 | 454.0 | 428.6 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 16.1 | 18.7 | 19.9 | 23.9 | 29.1 | 33.2 | 37.9 | 37.3 | 34.1 | 36.8 | 39.1 | 40.3 | 38.9 | 46.9 | 52.8 | 58.5 | 68.4 | 69.1 |
| Selling, General & Administrative Expenses (SG&A) | 120.3 | 155.9 | 152.5 | 159.3 | 177.7 | 187.7 | 191.1 | 218.1 | 234.9 | 228.7 | 233.0 | 239.8 | 242.6 | 262.9 | 272.7 | 302.0 | 362.8 | 316.9 | 353.4 | 338.5 |
% margin | 72.2 10.3% | 101.0 11.1% | 94.9 9.3% | 124.1 11.8% | 97.5 9.2% | 90.7 8.2% | 109.6 9.2% | 135.1 10.7% | 162.4 11.9% | 182.0 12.8% | 128.6 9.2% | 196.8 13.0% | 228.9 14.3% | 240.3 14.0% | 296.6 16.1% | 406.9 19.0% | 752.3 26.6% | 734.0 25.4% | 676.0 22.9% | 569.9 19.7% |
| Interest Income | 0.0 | 0.0 | 6.0 | 1.4 | 0.8 | 0.6 | 1.3 | 1.8 | 1.9 | 3.5 | 1.6 | 1.1 | 1.3 | 2.1 | 3.8 | 1.4 | 1.0 | 5.1 | 28.0 | 19.6 |
| Interest Expense | 0.0 | 0.0 | 14.5 | 16.0 | 14.4 | 16.8 | 18.2 | 14.9 | 15.1 | 13.0 | 12.5 | 7.0 | 6.5 | 6.3 | 4.7 | 6.8 | 7.2 | 7.9 | 9.0 | 3.0 |
| Pre-tax Income | 45.2 | 84.5 | 86.4 | 109.5 | 83.1 | 74.5 | 92.7 | 108.6 | 147.1 | 169.0 | 116.1 | 189.8 | 222.4 | 240.7 | 291.8 | 401.3 | 748.9 | 679.9 | 698.0 | 585.5 |
% effective tax rate | (0.4) (0.9%) | 24.6 29.1% | 17.2 19.9% | 23.7 21.6% | 13.5 16.2% | 13.6 18.3% | 23.5 25.4% | 32.7 30.1% | 40.2 27.3% | 47.2 27.9% | 26.3 22.7% | 54.4 28.7% | 80.9 36.4% | 41.4 17.2% | 59.0 20.2% | 72.5 18.1% | 107.2 14.3% | 114.7 16.9% | 122.3 17.5% | 107.5 18.4% |
% margin | 45.6 6.5% | 67.1 7.3% | 70.7 6.9% | 86.0 8.2% | 72.6 6.9% | 65.3 5.9% | 75.5 6.3% | 80.7 6.4% | 112.3 8.2% | 127.1 8.9% | 95.6 6.8% | 143.6 9.5% | 150.7 9.4% | 206.9 12.0% | 241.7 13.1% | 346.2 16.1% | 661.8 23.4% | 585.9 20.3% | 593.4 20.1% | 492.7 17.0% |
| EPS | 0.75 | 1.05 | 1.08 | 1.33 | 1.11 | 0.98 | 1.12 | 1.19 | 1.61 | 1.79 | 1.33 | 1.96 | 2.04 | 2.80 | 3.27 | 4.68 | 8.90 | 7.88 | 7.99 | 6.75 |
| Diluted EPS | 0.71 | 1.00 | 1.02 | 1.25 | 1.06 | 0.95 | 1.08 | 1.15 | 1.57 | 1.75 | 1.30 | 1.91 | 1.99 | 2.74 | 3.21 | 4.57 | 8.67 | 7.73 | 7.88 | 6.69 |
% margin | 122.9 17.6% | 149.9 16.4% | 157.5 15.4% | 186.1 17.7% | 166.4 15.8% | 161.3 14.6% | 183.4 15.4% | 200.0 15.8% | 249.0 18.2% | 273.3 19.2% | 220.0 15.7% | 319.6 21.2% | 335.9 21.0% | 355.3 20.7% | 399.4 21.7% | 531.7 24.8% | 895.2 31.6% | 887.9 30.8% | 844.1 28.6% | 743.9 25.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is West Pharmaceutical Services, Inc.'s Long-Term Investments?
As of today, West Pharmaceutical Services, Inc.'s last 12-month Long-Term Investments is $202.1M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is West Pharmaceutical Services, Inc.'s Long-Term Investments growth rate?
Over the last year, West Pharmaceutical Services, Inc.'s Long-Term Investments growth was (3.8%). The average annual Long-Term Investments growth rates for West Pharmaceutical Services, Inc. have been (1.5%) over the past three years, 1.0% over the past five years.
3) Is West Pharmaceutical Services, Inc.'s Long-Term Investments growth rate Good?
Over the last year, West Pharmaceutical Services, Inc.'s Long-Term Investments growth was (3.8%), which is lower than industry growth of (1.0%). It indicates that West Pharmaceutical Services, Inc.'s Long-Term Investments growth is Good.